AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2905187 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5000 units, three times daily)
Number of subjects: 1896
Study 12528545 — intervention group
Group type: EXPERIMENTAL
Intervention: Total flavones of Hippophae rhamnoides L. (TFH)
Number of subjects: 88
Study 12528545 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonist nifedipine
Number of subjects: 88
Study 12528545 — intervention group
Group type: COMPARATOR
Intervention: Verapamil ER
Number of subjects: 88
Study 31680083 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% amitriptyline gel
Number of subjects: 30
Study 31680083 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% amitriptyline mouthwash
Number of subjects: 30
Study 31680083 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional treatment
Number of subjects: 30
Study 29481765 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST-linked brief intervention (10-step BI) for illicit drug use
Number of subjects: 171
Study 29481765 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 171
Study 27267518 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl 6.0%
Number of subjects: 69
Study 27267518 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 69
Study 25481829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Navigation Intervention (TNI)
Number of subjects: 764
Study 25481829 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 764
Study 22763801 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg for weeks 1-4, 40 mg for weeks 5-8
Number of subjects: 941
Study 22763801 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)
Number of subjects: 941
Study 22763801 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium (LOS) 50 mg for weeks 1-4, 100 mg for weeks 5-8
Number of subjects: 941
Study 22763801 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium (LOS)
Number of subjects: 941
Study 20103392 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking stick
Number of subjects: 46
Study 17562406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-vastus split without patellar eversion
Number of subjects: 122
Study 17562406 — intervention group
Group type: COMPARATOR
Intervention: Mid-vastus split with patellar eversion
Number of subjects: 122
Study 17562406 — intervention group
Group type: COMPARATOR
Intervention: Median parapatellar arthrotomy without patellar eversion
Number of subjects: 122
Study 15611036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose supplementation during prolonged exercise
Number of subjects: 13
Study 15611036 — intervention group
Group type: COMPARATOR
Intervention: Placebo during prolonged exercise
Number of subjects: 13
Study 15611036 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exercise (3 hours)
Number of subjects: 13
Study 11907289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily for a minimum of 12 weeks
Number of subjects: 213
Study 11907289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks followed by 250 mg twice daily for a minimum of 12 weeks
Number of subjects: 213
Study 11907289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (both doses)
Number of subjects: 213
Study 11907289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 10331997 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent initiated preschool surveillance group
Number of subjects: 538
Study 10331997 — intervention group
Group type: COMPARATOR
Intervention: Conventional preschool surveillance group
Number of subjects: 538
Study 8579005 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (IT)
Number of subjects: 36
Study 8579005 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 36
Study 2505730 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate added to carbamazepine
Number of subjects: 15
Study 2505730 — intervention group
Group type: COMPARATOR
Intervention: Lithium alone
Number of subjects: 15
Study 2505730 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 15
Study 605912 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100 ppm of carbon monoxide for 1 hour
Number of subjects: 10
Study 605912 — intervention group
Group type: COMPARATOR
Intervention: Compressed, purified air for 1 hour
Number of subjects: 10
Study 30392864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral and motivational interviewing family-based weight loss treatment
Number of subjects: 186
Study 30392864 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued skills training
Number of subjects: 186
Study 30392864 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 186
Study 30392864 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention
Number of subjects: 186
Study 28237048 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining Abstinence (MA)
Number of subjects: 128
Study 28237048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Turkey (CT)
Number of subjects: 128
Study 28237048 — intervention group
Group type: EXPERIMENTAL
Intervention: Winding Down (WD)
Number of subjects: 128
Study 28237048 — intervention group
Group type: COMPARATOR
Intervention: Generalized Estimating Equations (GEE) analyses
Number of subjects: 128
Study 28237048 — intervention group
Group type: COMPARATOR
Intervention: Early treatment PDD (weeks 1‐7)
Number of subjects: 128
Study 25492848 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) sustained-release drug under fasting conditions
Number of subjects: 60
Study 25492848 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) sustained-release drug under fed conditions
Number of subjects: 60
Study 24290112 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised light‐ to moderate‐intensity exercise intervention (3 days a week, 50‐55 minutes per session)
Number of subjects: 962
Study 24290112 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 962
Study 21622825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ascorbate (10 mM)
Number of subjects: 11
Study 21622825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 11
Study 21622825 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 11
Study 19500381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (500 mg iron polymaltose, single dose)
Number of subjects: 100
Study 19500381 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (2 ferrous sulphate slow-release tablets daily)
Number of subjects: 100
Study 16686720 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ethanol in 1.5% glycine irrigation fluid
Number of subjects: 120
Study 14611916 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative thoracic radiotherapy
Number of subjects: 3000
Study 11763947 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Cure (Optilux 401) for 60 s
Number of subjects: 120
Study 11763947 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Curing (Elipar Highlight) for 10 s low intensity followed by 50 s high intensity
Number of subjects: 120
Study 8964851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND)
Number of subjects: 3
Study 8964851 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (SP)
Number of subjects: 3
Study 8964851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 2000902 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial tenonectomy
Number of subjects: 49
Study 2000902 — intervention group
Group type: COMPARATOR
Intervention: Total tenonectomy
Number of subjects: 49
Study 6391157 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily for three weeks)
Number of subjects: 63
Study 6391157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 6391157 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 63
Study 30644762 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus plus miniplates (FMP)
Number of subjects: 48
Study 30644762 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FFRD)
Number of subjects: 48
Study 30644762 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniplates
Number of subjects: 48
Study 29409728 — intervention group
Group type: COMPARATOR
Intervention: Extended-release niacin (ERN) treatment
Number of subjects: 2754
Study 29409728 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GlycA levels
Number of subjects: 2754
Study 29409728 — intervention group
Group type: EXPERIMENTAL
Intervention: In-trial GlycA levels
Number of subjects: 2754
Study 29409728 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of small HDL particles (baseline)
Number of subjects: 2754
Study 29409728 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of small HDL particles (in-trial)
Number of subjects: 2754
Study 26616764 — intervention group
Group type: EXPERIMENTAL
Intervention: Calisthenic exercise
Number of subjects: 47
Study 26616764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise
Number of subjects: 47
Study 26616764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 47
Study 24588631 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 476
Study 24588631 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 476
Study 22193342 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 × 10 protocol
Number of subjects: 10
Study 22193342 — intervention group
Group type: EXPERIMENTAL
Intervention: Speedo Resistance Equipment (W situation)
Number of subjects: 10
Study 22193342 — intervention group
Group type: COMPARATOR
Intervention: No Speedo Resistance Equipment (WO situation)
Number of subjects: 10
Study 22193342 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise analysis with Speedo Resistance Equipment (W situation)
Number of subjects: 10
Study 21056314 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose GnRH agonist flare (MF)
Number of subjects: 94
Study 21056314 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist/letrozole
Number of subjects: 94
Study 17432075 — intervention group
Group type: EXPERIMENTAL
Intervention: DARS-group (1 MAC desflurane; remifentanil: 0.2 microg x kg(‐1) x min(‐1))
Number of subjects: 100
Study 17432075 — intervention group
Group type: COMPARATOR
Intervention: RADS-group (desflurane: 0.5 MAC; remifentanil: 0.4 microg x kg(‐1) x min(‐1))
Number of subjects: 100
Study 17432075 — intervention group
Group type: EXPERIMENTAL
Intervention: DARS-group
Number of subjects: 100
Study 17432075 — intervention group
Group type: COMPARATOR
Intervention: RADS-group
Number of subjects: 100
Study 15910732 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-call surgeons (32)
Number of subjects: 64
Study 15910732 — intervention group
Group type: COMPARATOR
Intervention: Post-work surgeons (32)
Number of subjects: 64
Study 15910732 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons (64)
Number of subjects: 64
Study 15910732 — intervention group
Group type: COMPARATOR
Intervention: Nurses (64)
Number of subjects: 64
Study 12042457 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 microg of folate
Number of subjects: 211
Study 12042457 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of vitamin B-12
Number of subjects: 211
Study 12042457 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of vitamin B-6
Number of subjects: 211
Study 12042457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 9504355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 0
Study 9504355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0
Study 9504355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7999930 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Number of subjects: 0
Study 7999930 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 0
Study 7999930 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric placebo meal
Number of subjects: 0
Study 7999930 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 0
Study 3142984 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral lipid infusion (IL) (Vitrum)
Number of subjects: 42
Study 3142984 — intervention group
Group type: COMPARATOR
Intervention: No parenteral lipid infusion (NL)
Number of subjects: 42
Study 30139562 — intervention group
Group type: EXPERIMENTAL
Intervention: MEND2-5
Number of subjects: 549
Study 30139562 — intervention group
Group type: EXPERIMENTAL
Intervention: MEND/CATCH6-12
Number of subjects: 549
Study 30139562 — intervention group
Group type: COMPARATOR
Intervention: Next Steps
Number of subjects: 549
Study 29037632 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial dry needling
Number of subjects: 30
Study 29037632 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling
Number of subjects: 30
Study 29037632 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 26479162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen (5 mg/325 mg)
Number of subjects: 220
Study 26479162 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone/Acetaminophen (5 mg/325 mg)
Number of subjects: 220
Study 26479162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 220
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 750 mg/day
Number of subjects: 200
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 1500 mg/day
Number of subjects: 200
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg/day
Number of subjects: 200
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 320 mg/day
Number of subjects: 200
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 200
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 200
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 200
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 200
Study 24521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 200
Study 22704426 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP (mitomycin-ifosfamide-cisplatin)
Number of subjects: 140
Study 22704426 — intervention group
Group type: EXPERIMENTAL
Intervention: GVP (gemcitabine-vinorelbine-cisplatin)
Number of subjects: 140
Study 19162468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (40-120 microg, administered as intermittent i.v. bolus)
Number of subjects: 50
Study 19162468 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (intermittent boluses)
Number of subjects: 50
Study 17204681 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (unfractionated heparin or low‐molecular‐weight heparin or heparinoids)
Number of subjects: 4624
Study 15015607 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stenting
Number of subjects: 18
Study 15015607 — intervention group
Group type: COMPARATOR
Intervention: Surgery (Gastroenterostomy)
Number of subjects: 18
Study 11257244 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg p.o., approximately 2‐3 standard drinks)
Number of subjects: 9
Study 11257244 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled alcohol intake (0.8 g/kg/day)
Number of subjects: 9
Study 11257244 — intervention group
Group type: COMPARATOR
Intervention: Placebo conditions
Number of subjects: 9
Study 9444594 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-PDGF/IGF-I (50 micrograms/ml each of rhPDGF-BB and rhIGF-I in a gel vehicle)
Number of subjects: 38
Study 9444594 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-PDGF/IGF-I (150 micrograms/ml each of rhPDGF-BB and rhIGF-I plus vehicle)
Number of subjects: 38
Study 9444594 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional periodontal flap surgery or surgery plus vehicle)
Number of subjects: 38
Study 7524312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid antibody testing for hepatitis C
Number of subjects: 216
Study 3226754 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dosage Regimen (HDR; n = 51) - NS 550 mg every 8 h for 3 days
Number of subjects: 100
Study 3226754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dosage Regimen (LDR; n = 49) - Initial dose of NS 550 mg followed by NS 275 mg every 8 h through day 3
Number of subjects: 100
Study 2192301 — intervention group
Group type: EXPERIMENTAL
Intervention: DGAVP citrate (Org 5667)
Number of subjects: 115
Study 2192301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 4132247 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH/LH-RH treatment
Number of subjects: 16
Study 4132247 — intervention group
Group type: COMPARATOR
Intervention: Unstimulated controls
Number of subjects: 16
Study 31452420 — intervention group
Group type: EXPERIMENTAL
Intervention: CTHC (thermochemotherapy with pirarubicin)
Number of subjects: 300
Study 31452420 — intervention group
Group type: COMPARATOR
Intervention: THP (instillation of pirarubicin without hyperthermia)
Number of subjects: 300
Study 28103841 — intervention group
Group type: COMPARATOR
Intervention: Usual Nicotine Content (11.6 mg)
Number of subjects: 200
Study 28103841 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content (progressively reduced from 11.6 mg to 0.2 mg)
Number of subjects: 200
Study 26252522 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg (NMBA group)
Number of subjects: 160
Study 26252522 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (No‐NMBA group)
Number of subjects: 160
Study 23627835 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management (SM) group
Number of subjects: 34
Study 23627835 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 21237635 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual and manipulative therapy (MMT)
Number of subjects: 30
Study 21237635 — intervention group
Group type: COMPARATOR
Intervention: Night splint (control)
Number of subjects: 30
Study 18783735 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731
Study 18783735 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 731
Study 17302600 — intervention group
Group type: COMPARATOR
Intervention: EC‐MPS
Number of subjects: 246
Study 14740329 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional diet education (20 to 30 minutes per month)
Number of subjects: 63
Study 14740329 — intervention group
Group type: COMPARATOR
Intervention: Routine laboratory results review (control group)
Number of subjects: 63
Study 11139557 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible hysteroscope
Number of subjects: 142
Study 11139557 — intervention group
Group type: COMPARATOR
Intervention: Rigid hysteroscope
Number of subjects: 142
Study 10196853 — intervention group
Group type: EXPERIMENTAL
Intervention: Debacterol
Number of subjects: 60
Study 10196853 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenalog-in-Orabase
Number of subjects: 60
Study 10196853 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 7879405 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain management
Number of subjects: 46
Study 7879405 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization techniques
Number of subjects: 46
Study 7879405 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 46
Study 7879405 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (control)
Number of subjects: 46
Study 3344600 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol plus diazepam
Number of subjects: 0
Study 3344600 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl plus diazepam
Number of subjects: 0
Study 31891824 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis (wP) vaccination
Number of subjects: 0
Study 31891824 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dose as wP
Number of subjects: 0
Study 31891824 — intervention group
Group type: EXPERIMENTAL
Intervention: wP-only
Number of subjects: 0
Study 31891824 — intervention group
Group type: COMPARATOR
Intervention: aP vaccination
Number of subjects: 0
Study 28699850 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training intervention (exercises on balance devices)
Number of subjects: 19
Study 28699850 — intervention group
Group type: COMPARATOR
Intervention: Control group (breathing exercises and aerobic physical training, six times/week, 45 minutes)
Number of subjects: 19
Study 27465028 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks' training in book sharing
Number of subjects: 91
Study 27465028 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 91
Study 23845010 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective family‐focused violence prevention program
Number of subjects: 334
Study 23845010 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal intervention composed of a student social‐cognitive curriculum and teacher training
Number of subjects: 334
Study 23845010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of universal and selective interventions
Number of subjects: 334
Study 23845010 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 334
Study 21963145 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-day balance training (group A)
Number of subjects: 26
Study 21963145 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 26
Study 21963145 — intervention group
Group type: COMPARATOR
Intervention: Group B (without training)
Number of subjects: 26